OPRX — OptimizeRx Income Statement
0.000.00%
Last trade - 00:00- $123.08m
- $125.39m
- $109.43m
Annual income statement for OptimizeRx, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 61.3 | 62.5 | 71.5 | 92.1 | 109 |
| Cost of Revenue | |||||
| Gross Profit | 35.6 | 39 | 42.9 | 59.4 | 73.6 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 60.9 | 74.7 | 97.9 | 106 | 97.7 |
| Operating Profit | 0.361 | -12.3 | -26.4 | -13.7 | 11.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 0.378 | -11.4 | -25.2 | -19.4 | 6.95 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 0.378 | -11.4 | -17.6 | -20.1 | 5.13 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 0.378 | -11.4 | -17.6 | -20.1 | 5.13 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 0.378 | -11.4 | -17.6 | -20.1 | 5.13 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.021 | -0.643 | -0.689 | -0.833 | 0.284 |